Appendix A. ICD10 Diagnosis Codes

ICD10 Diagnosis Code	Description
R65.21	Severe sepsis with septic shock
A02.1	Salmonella sepsis
A22.7	Anthrax sepsis
A26.7	Erysipelothrix sepsis
A32.7	Listerial sepsis
A40.0	Sepsis due to streptococcus, group A
A40.1	Sepsis due to streptococcus, group B
A40.3	Sepsis due to Streptococcus pneumoniae
A40.8	Other streptococcal sepsis
A40.9	Streptococcal sepsis, unspecified
A41.01	Sepsis due to Methicillin susceptible Staphylococcus aureus
A41.02	Sepsis due to Methicillin resistant Staphylococcus aureus
A41.1	Sepsis due to other specified staphylococcus
A41.2	Sepsis due to unspecified staphylococcus
A41.3	Sepsis due to Hemophilus influenzae
A41.4	Sepsis due to anaerobes
A41.50	Gram-negative sepsis, unspecified
A41.51	Sepsis due to Escherichia coli [E. coli]
A41.52	Sepsis due to Pseudomonas
A41.53	Sepsis due to Serratia
A41.81	Sepsis due to Enterococcus
A41.89	Other specified sepsis
A41.9	Sepsis, unspecified organism

A42.7	Actinomycotic sepsis
A54.86	Gonococcal sepsis
B37.7	Candidal sepsis
R65.20	Severe sepsis without septic shock

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	2	Retrospective cohort study as stated in the Abstract (page 3)
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found		Provided in Abstract on page 3
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported		Included in the Introduction on page 7-8.
Objectives	3	State specific objectives, including any prespecified hypotheses		Included in the Introduction on page 7-8.
Methods				
Study design	4	Present key elements of study design early in the paper		Included in the Materials and Methods on page 8-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection		Included in the Materials and Methods on pages 8-9
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants		Included in the Materials and Methods on pages 8-9
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case		Included in the Materials and Methods on pages 8-9
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable		Included in the Materials and Methods on pages 8-9

Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Included in the Materials and Methods on pages 8-9
Bias	9	Describe any efforts to address potential sources of bias	Included in the Materials and Methods on pages 8-9
Study size	10	Explain how the study size was arrived at	Included in the Materials and Methods on pages 8-9

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Included in the Materials and Methods on pages 8-9
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Included in the Materials and Methods on pages 8-9
		(*b*) Describe any methods used to examine subgroups and interactions	Included in the Materials and Methods on pages 8-9
		(*c*) Explain how missing data were addressed	Included in the Materials and Methods on pages 8-9
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	Not applicable.
		(*e*) Describe any sensitivity analyses	Not applicable.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Included in the Results on pages 10 and 11.
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not required
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Included in the Results on pages 10 and 11.
		(b) Indicate number of participants with missing data for each variable of interest	Included in the Results on pages 10 and 11.
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	Included in the Results on pages 10 and 11.
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	Included in the Results on pages 10 and 11.
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures	
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Included in the Results on pages 10 and 11.

	(*b*) Report category boundaries when continuous variables were categorized	Included in the Results on pages 10 and 11.
	(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Included in the Results on pages 10 and 11.
Discussion			
Key results	18	Summarise key results with reference to study objectives	Included in the Discussion on page 11-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Included in the Discussion on page 11-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Included in the Discussion on page 11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	Included in the Discussion on page 11-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Not applicable

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.